Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Margrit Wiesendanger, MD, PhD, discusses how lupus treatment is evolving from traditional therapies to more targeted options like biologics, with promising advances now being explored in clinical ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...

U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...

By elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns ...

Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...

Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics ...

Granlab, a Queen’s University spin-in founded by Dr Pragya Sharma, opens new lab in Belfast to commercialise steroid-free ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

While patients with psoriasis -- a chronic skin condition -- respond well to treatment with biologics, inflammation can ...